UK-based AI biotechnology company, Antiverse, has raised GBP 2.5 million (USD 3 million) from various investors, including InnoSpark, AngelHub, and Tensor Ventures. The round brings the company’s total funds raised to date to GBP 4.3 million (USD 5.2 million).
The proceeds were earmarked for the in-house development of antibodies that show high-affinity blocking function; i.e the ability to tightly and specifically bind to a target molecule, preventing its normal function and interfering with its interactions with other molecules.
Simultaneously, the company announced the discovery of eight therapeutic antibodies using its proprietary AI-powered platform. The antibodies will target two G-protein-coupled receptors (GPCRs), of which seven have been characterized and will be developed in-house.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.